CADL - NASDAQ
Candel Therapeutics, Inc.
$8.42
+4.5%Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was incorporated in 2003 and is based in Needham, Massachusetts.
At a Glance
Live SnapshotCandel Therapeutics, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Elevated leverage. Debt exceeds equity, which amplifies both gains and risks. Monitor debt servicing ability.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Candel Therapeutics, Inc. Balance Sheet
CADL • NASDAQ
| Candel Therapeutics, Inc. Balance Sheet | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
ASSETS | |||||||
CURRENT ASSETS | |||||||
119.7M | 102.7M | 35.4M | 70.1M | 82.6M | 35.1M | 5.2M | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 39.9M | |
119.7M | 102.7M | 35.4M | 70.1M | 82.6M | 35.1M | 45.1M | |
0.0 | 1.2M | 0.0 | 0.0 | 0.0 | 93K | 153K | |
0.0 | 0.0 | 1.4M | 1.9M | 2.3M | 0.0 | 0.0 | |
119.7M | 103.8M | 36.8M | 71.9M | 84.9M | 35.1M | 45.2M | |
NON-CURRENT ASSETS | |||||||
0.0 | 2.7M | 4M | 5.5M | 3.8M | 2.8M | 425K | |
416K | 0.0 | 0.0 | 266K | 424K | 0.0 | 266K | |
0.0 | 0.0 | 0.0 | 828K | 0.0 | 0.0 | 0.0 | |
5M | 329K | 382K | 0.0 | 0.0 | 349K | 0.0 | |
5.5M | 3.1M | 4.4M | 6.6M | 4.3M | 3.1M | 691K | |
125.2M | 106.9M | 41.2M | 78.5M | 89.2M | 38.3M | 45.9M | |
LIABILITIES | |||||||
CURRENT LIABILITIES | |||||||
1.1M | 237K | 422K | 380K | 1.6M | 921K | 218K | |
1.1M | 237K | 422K | 380K | 1.6M | 921K | 218K | |
0.0 | 4.7M | 2M | 2.6M | 2.1M | 3.1M | 577K | |
445K | 9.9M | 8.9M | 464K | 0.0 | 463K | 0.0 | |
0.0 | 566K | 513K | 0.0 | 0.0 | 0.0 | 0.0 | |
7.4M | 22.1M | 2.3M | 2.1M | 1.7M | 187K | 615K | |
9M | 37.5M | 14.2M | 5.6M | 5.4M | 4.7M | 1.4M | |
NON-CURRENT LIABILITIES | |||||||
1.5M | 2.6M | 12.4M | 20.9M | 560K | 483K | 420K | |
0.0 | 0.0 | 0.0 | 144K | 0.0 | 125K | 250K | |
0.0 | 0.0 | 0.0 | 828K | 0.0 | 0.0 | 0.0 | |
62.8M | 0.0 | 916K | 1.9M | 19.1M | 56.5M | 51.9M | |
64.3M | 3M | 14.3M | 25.2M | 19.7M | 57.1M | 52.5M | |
0.0 | 973K | 1.5M | 1.5M | 0.0 | 0.0 | 0.0 | |
73.3M | 40.5M | 28.5M | 30.8M | 25.1M | 61.8M | 53.9M | |
SHAREHOLDERS' EQUITY | |||||||
-448K | -448K | -448K | -448K | 0.0 | 0.0 | -18.2M | |
0.0 | 0.0 | 0.0 | 0.0 | 89.2M | 0.0 | 49.1M | |
550K | 469K | 290K | 290K | 286K | 116K | 116K | |
282.2M | 258.5M | 149.9M | 147M | 144.1M | 20.5M | 18.2M | |
-230.4M | -192.2M | -137M | -99.1M | -80.3M | -44.2M | -26.5M | |
0.0 | 0.0 | 0.0 | 0.0 | -89.2M | 0.0 | -19K | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -30.7M | |
51.9M | 66.3M | 12.7M | 47.7M | 64.1M | -23.6M | -8M | |
51.9M | 66.3M | 12.7M | 47.7M | 64.1M | -23.6M | -8M | |
SUMMARY | |||||||
125.2M | 106.9M | 41.2M | 78.5M | 89.2M | 38.3M | 45.9M | |
416K | 0.0 | 0.0 | 266K | 424K | 0.0 | 39.9M | |
1.9M | 13.5M | 22.8M | 22.8M | 560K | 946K | 420K | |
-117.8M | -89.2M | -12.7M | -47.3M | -82.1M | -34.1M | -4.8M | |
54,900,218 | 54,900,218 | 54,900,218 | 54,900,218 | 54,900,218 | 54,900,218 | 54,900,218 |
SEC Filings
CADL - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 15, 2026 | May 15, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 14, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 14, 2026 | May 14, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 29, 2026 | June 23, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 12, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 12, 2026 | March 12, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 23, 2026 | February 19, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 19, 2026 | February 19, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 05, 2025 | December 05, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 13, 2025 | November 13, 2025 | 2025 |
Related Guides
Continue your CADL research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.